ZLAB (zailaboratory.com) Market Value to Book Value Ratio

Official company branding of Zai Lab Ltd (ZLAB)

The available price action for Zai Lab Limited (ZLAB) reflects the dynamics of an asset that monetizes Western developments in China, extracting high profits from exclusive rights to oncology drugs. The business leverages strong market positions and inelastic demand for innovation, reaching a figure of 4.49. Cost efficiency is maintained through flexible outsourcing of clinical trials and contract drug manufacturing.

ZLAB Zai Lab Corp: Market Value to Book Value in the range 07/04/2022 - 10/26/2026

Financial and market metric breakdowns for Zai Lab Ltd (ZLAB)

- price and consensus price forecast:
Stock Price Zai Lab Limited|ZLAB - Price Target Chart
- market capitalization data:
Market Value Zai Lab Ltd.|ZLAB - Full Business Value
- book capitalization data:
Book Value per Share Zai Lab|ZLAB - Accounting Value of Company|Market Capitalization to Book Value Ratio zailaboratory.com|ZLAB - Company Total Assets
- debt and liquidity data:
Debt to Equity Zai Lab Limited|ZLAB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Zai Lab Ltd.|ZLAB - Company Total Debt|Debts to Book Capitalization Zai Lab Ltd.
Initial company analysis:Zai Lab Limited - ZLAB
Original product of Zai Lab Ltd.

This ratio measures the market value premium over net assets, revealing the degree of speculative optimism among investors regarding the company's capital. Analyzing the chart of the market cap to book value ratio allows for an assessment of overvaluation risks for Zai Lab Limited (ZLAB), where high asset valuation is driven by expectations for the commercialization of innovative oncology drugs in Chinese markets.

Main competitors

Eli Lilly and Company (LLY) - Market Capitalization to Book Value Ratio|ABBV (abbvie.com) - Market Value to Book Value Ratio|Market Value to Book Value Ratio AstraZeneca AZN|Market Capitalization to Net Assets Novartis Corporation|Merck Sharp & Dohme (MRK) - Market Capitalization to Book Value Ratio|Market Value to Book Value Novo Nordisk Group (NVO)|Market Capitalization to Book Value Ratio AMGN (Amgen Inc.)|pfizer.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Sanofi S.A. (SNY)|BMY: Market Value to Book Value|GSK (gsk.com) - Market Value to Book Value Ratio|Takeda Pharma (TAK) - Market Cap to Net Assets Ratio|TEVA (Teva Pharmaceutical Industries Limited) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio drreddys.com (RDY)|Viatris (VTRS) - Market Cap to Net Assets Ratio|Market Value to Book Value Roivant (ROIV)|Market Capitalization to Book Value Ratio Valeant Pharmaceuticals|Cosmos Health Inc - Market Value to Book Value